Cingulate (CING) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
18 Feb, 2026Executive summary
Special Meeting scheduled for March 24, 2026, to approve key proposals related to a recent private placement and capital structure changes.
Proposals include approval for issuance of common stock upon conversion of Series A Convertible Preferred Stock and exercise of warrants, and potential adjournment if more votes are needed.
Private Placement raised approximately $12 million, with proceeds intended for working capital and general corporate purposes.
Voting matters and shareholder proposals
Stockholders will vote on the Issuance Proposal (approval for issuing common stock upon conversion of preferred stock and/or exercise of warrants) and the Adjournment Proposal (to adjourn the meeting if more votes are needed).
Board unanimously recommends voting FOR both proposals.
If the Issuance Proposal is not approved, meetings will recur every three months until approval is obtained.
Board of directors and corporate governance
Falcon Creek Capital Advisor LLC, as lead investor, gains the right to designate up to two directors on the Board, contingent on stockholder approval and ownership thresholds.
Upon approval, Falcon Creek will have two of seven Board seats.
Board size increased to accommodate new director designations.
Latest events from Cingulate
- CTX-1301 aims to disrupt the ADHD market with once-daily efficacy and strong clinical results.CING
Corporate presentation14 Apr 2026 - Advancing once-daily ADHD and anxiety drugs with $12M raised, but faces going concern risk.CING
Registration filing14 Apr 2026 - Shelf registration enables flexible securities issuance; auditor consent updated.CING
Registration filing23 Mar 2026 - Up to 3.5M shares may be sold to Lincoln Park for up to $25M to fund CNS drug development.CING
Registration filing20 Mar 2026 - Beneficial ownership table updated to include a 5% stockholder and clarify voting procedures.CING
Proxy Filing18 Mar 2026 - 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised.CING
Q4 202518 Mar 2026 - Approval sought for stock issuance and board changes following a $12M private placement.CING
Proxy Filing2 Mar 2026 - Biopharma targets ADHD market with $200M shelf registration amid financial uncertainty.CING
Registration Filing12 Jan 2026 - Registering 6.63M shares for resale tied to ADHD drug warrants, with proceeds for operations.CING
Registration Filing16 Dec 2025